文献速递甲状腺核医学肿瘤 PET/CT

[18F]TFB PET/CT在转移性甲状腺癌再分化治疗后漏诊强烈摄[124I]碘的转移灶

[18F]TFB PET/CT misses intense [124I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.
PubMed 文献 · EJNMMI Res · 2024-10-08

前瞻性初步研究纳入5例转移性甲状腺癌患者,同日行[18F]TFB PET/CT与[124I]碘PET/CT。3例低分化甲状腺癌接受曲美替尼再分化治疗。再分化治疗前/未再分化时33个病灶中,[18F]TFB检出19个(58%),[124I]碘检出30个(91%)。再分化治疗后[124I]碘新发现48个病灶(中位SUVmax 3.3,范围0.4-285.0),均为[18F]TFB阴性。

要点

  • 在低分化甲状腺癌接受曲美替尼再分化治疗的患者中,[18F]TFB未能预测放射性碘摄取。
  • 再分化治疗后[124I]碘新发现的48个病灶均为[18F]TFB阴性。
  • 再分化治疗前/未再分化时,[18F]TFB检出率58%(19/33),[124I]碘检出率91%(30/33)。

核心结论

  • [18F]TFB未能预测接受曲美替尼再分化治疗的低分化甲状腺癌患者的放射性碘摄取。
  • 尚不清楚此类差异是否也见于其他再分化治疗或甚至未接受再分化治疗的甲状腺癌。

研究设计与样本

  • 前瞻性初步研究,纳入5例转移性甲状腺癌患者。
  • 所有患者注射356 ± 12 MBq [18F]TFB后1小时行PET/CT,同日口服230 ± 9 MBq [124I]碘,48小时后行PET/CT。
  • 再分化治疗前患者额外接受基线[124I]碘PET/CT。
  • 由两名委员会认证专家分析病例,计算[18F]TFB与[124I]碘的检出率和Spearman相关系数。
  • 3例低分化甲状腺癌在再分化试验中接受曲美替尼;2例乳头状甲状腺癌未接受再分化治疗。

主要发现

  • 再分化治疗前/未再分化时共见33个病灶,[18F]TFB可见19个(58%),[124I]碘可见30个(91%)。
  • 接受再分化治疗的患者中,[124I]碘PET/CT新发现48个病灶,中位SUVmax为3.3(范围0.4-285.0)。
  • 上述48个再分化治疗后新发现的病灶均为[18F]TFB阴性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fluorine 18-labelled tetrafluoroborate ([18F]TFB) is a substrate for the sodium/iodide symporter. In thyroid cancer, [18F]TFB-PET/CT may be an alternative to iodine imaging to evaluate the extent of disease, eligibility for radioiodine treatment, and success of redifferentiation therapies. We report the results of a pilot study to determine tumor uptake of [18F]TFB and compare its properties to [124I]IodinePET/CT in patients with metastatic thyroid cancer. METHODS: Five patients were included in a prospective study. All patients received PET/CT 1 h after injection of 356 ± 12 MBq [18F]TFB and were given 230 ± 9 MBq [124I]Iodine orally on the same day, followed by PET/CT after 48 h. Before redifferentiation therapy, patients underwent an additional baseline [124I]Iodine PET/CT. Cases were analyzed by two board-certified specialists. Detection rates and Spearman correlation for [18F]TFB and [124I]Iodine were calculated. RESULTS: Three patients had poorly differentiated thyroid cancer and received trametinib in a redifferentiation trial. Two patients had papillary thyroid cancer and did not receive redifferentiation therapy. Of the 33 lesions seen before/without redifferentiation therapy, 19 (58%) were visible on [18F]TFB and 30 (91%) on [124I]Iodine imaging. In the patients who underwent redifferentiation therapy, 48 lesions were newly seen on [124I]Iodine PET/CT with a median SUVmax of 3.3 (range, 0.4-285.0). All of these lesions were [18F]TFB-negative. CONCLUSION: [18F]TFB failed to predict radioactive iodine uptake in patients with poorly differentiated thyroid cancer who underwent redifferentiation therapy with trametinib. It is unclear whether such discrepancies may also occur in other redifferentiation therapies or may even be encountered in redifferentiation-naïve thyroid cancer. TRIAL REGISTRATION NUMBER: NCT03196518, registered on June 22, 2017.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Backhaus P, Pentlow KS, Ho AL, et al. [18F]TFB PET/CT misses intense [124I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer. EJNMMI Res. 2024. PMID: 39377970. doi:10.1186/s13550-024-01138-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。